Board of Directors


Jean-François Le BigotJean-François Le Bigot, PhD – CEO

Jean-François Le Bigot has long and extensive experience in drug development combined with the executive management of private companies through major growth cycles and Private Equity investments. He is the former President, CEO and shareholder of Citoxlab Group, one of the leading international non-clinical Contract Research Organizations (CRO). From 1987 to 2019, Jean-Francois Le Bigot transformed Centre International de la Toxicologie (CIT), a single site French non-clinical CRO with 120 staff, into the internationally recognized Citoxlab brand that includes today 8 research centers located in 5 countries and employs more than 1 500 people. After his PhD in Pharmacology and Biochemistry, Jean-Francois Le Bigot started his industrial career at Sandoz Laboratories (now Novartis) as Head of Experimental Biology and then Director of Pre-Clinical Development in France.

Frédéric TangyFrédéric Tangy, PhD, Dr.Sc. – Founder and CSO

Frédéric Tangy is the inventor of the recombinant measles virus technology at the core of Oncovita’s therapeutic anticancer approach. With 30 years of expertise in virology and vaccinology, he is author of over 150 research publications and principal inventor of 25 international patents. He has headed two major research programs: development of viral vaccines based on measles vaccine vector, and systematic study of the interactions between virus and host proteins using high-throughput functional genomic methods. Several of his research programs have led to industrial breakthroughs in the field of prophylactic and therapeutic vaccines in collaboration with GSK, Transgene and Themis Bioscience. In addition to his primary research activity as head of the Viral Genomics and Vaccination Unit at Institut Pasteur, Frédéric Tangy founded the International Vaccinology Course and was member and VP of the Pasteur Scientific Council. As CSO, Frédéric Tangy will lead the translation of Oncovita’s candidates from the bench to the clinic.

Patrick Spies - OncovitaPatrick Spies, CFO

Graduate from Institut Etudes Politiques Paris, Executive MBA and Harvard Business School is the CFO of the company. He was previously General Manager, Administration and Finance at Hachette Filipacchi media and then at Groupe Beauvallet. Before joining Oncovita, Mr. Spies has been Executive Vice President Corporate Development (M&A operations) at Citoxlab Group for twelve years. He has an extended expertise in finance, investors relations, legal compliance, management of M&A operations.

Charles WolerCharles Woler, MD, PhD, MBA

Charles Woler is a multi-cultural executive with more than 40 years of diverse experience in Pharmaceutical/Biotech/Medtech/Bio-pathology in Europe and USA. He also has 12 years of experience in Healthcare Private Equity. He has an extensive background in management, strategic planning and marketing, operations and business development, thanks to numerous General Manager and CEO positions in big pharma, biotech, diagnostics companies, i.e. CEO Roche France, President Europe SKB, CEO neuro3D, Endotis, Chairman or Member of the Board of Biomnis, Synexus, Proclif, France, Imclone System, USA, InflamAlps, Switzerland, NovelluxDX and Ocon Medical, Israel. Charles is Associate Professor in Strategy, Management and Organization, Paris University.

Mission and vision

Management team


Scientific Advisory Board